Biological activities of fibroblast growth factor-2 in the adult myocardium

Cardiovascular Research

Volumn 57, Issue 1, 2003, Pages 8-19

  Detillieux, Karen A ^a   Sheikh, Farah ^a,b   Kardami, Elissavet ^a   Cattini, Peter A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Growth factors; Hypertrophy; Ischemia; Signal transduction

Indexed keywords

ANTIBODY; CD3 ANTIBODY; CHELERYTHRINE; CONNEXIN 43; CYCLOSPORIN A; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLIBENCLAMIDE; ISOPRENALINE; NEUTRALIZING ANTIBODY; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN KINASE C INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FIBROBLAST; GAP JUNCTION; HEART CONDUCTION; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOTENSION; INOTROPISM; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SLOW DRUG RELEASE; SMOOTH MUSCLE FIBER; STABLE ANGINA PECTORIS; STUNNED HEART MUSCLE; TREATMENT OUTCOME;

ADULT; ANIMALS; CARDIOMEGALY; CONTRACTILE PROTEINS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; MUSCLE CELLS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0037216633     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00708-3     Document Type: Review

References (147)

1. Cooke R. Dr Folkman's war: angiogenesis and the struggle to defeat cancer. 2000;Random House, New York. 130 pp.
2. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem. 250:1975;2515-2520.
3. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 277:2000;494-498.
4. Ferrara N., Houck K.A., Jakeman L.B., Winer J., Leung D.W. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 47:1991;211-218.
5. Peipkorn M., Pittelkow M.R., Cook P.W. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol. 111:1998;715-721.
6. Szebenyi G., Fallon J.F. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol. 185:1999;45-106.
7. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 59:1992;115-165.
8. Kardami E., Padua R.R., Doble B.W., Sheikh F., Cattini P.A. Signaling cascades mediating the pleiotropic actions of FGF-2 on cardiac myocytes. Cuevas P. Fibroblast growth factor in the cardiovascular system. 2002;. in press.
9. Florkiewicz R.Z., Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons. Proc Natl Acad Sci USA. 86:1989;3978-3981.
10. Vagner S., Gensac M.-L., Maret A., et al. Alternative translation of human fibroblast growth factor-2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol. 15:1995;35-44.
11. Arnaud E., Touriol C., Boutonnet C., et al. New 34-kilodalton isoform of human fibroblast growth factor-2 is cap-dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol. 19:1999;505-514.
12. Szebenyi G., Fallon J.F. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol. 185:1999;45-106.
13. Cummins P. Fibroblast and transforming growth factor expression in the cardiac myocyte. Cardiovasc Res. 27:1993;1150-1154.
14. Kardami E., Liu L., Pasumarthi K.B.S., Doble B.W., Cattini P.A. Regulation of basic fibroblast growth factor (bFGF) and FGF receptors in the heart. Ann NY Acad Sci. 752:1995;353-369.
15. Liu L., Doble B.W., Kardami E. Perinatal phenotype and hypothyroidism are associated with elevated levels of 21.5- to 22-kDa basic fibroblast growth factor in cardiac ventricles. Dev Biol. 157:1993;507-516.
16. Pasumarthi K.B.S., Doble B.W., Kardami E., Cattini P.A. Over-expression of CUG- or AUG-initiated forms of basic fibroblast growth factor in cardiac myocytes results in similar effects on mitosis and protein synthesis but distinct nuclear morphologies. J Mol Cell Cardiol. 26:1994;1045-1060.
17. Pasumarthi K.B.S., Kardami E., Cattini P.A. High and low molecular weight fibroblast growth factor-2 increase proliferation of neonatal rat cardiac myocytes but have differential effects on binucleation and nuclear morphology. Evidence for both paracrine and intracrine actions of fibroblast growth factor-2. Circ Res. 78:1996;126-136.
18. Sun G., Doble B.W., Sun J.M., et al. CUG-initiated FGF-2 induces chromatin compaction in cultured cardiac myocytes and in vitro. J. Cell. Physiol. 186:2001;457-467.
19. Sugi Y., Sasse J., Barron M., Lough J. Developmental expression of fibroblast growth factor receptor-1 (cek-1; flg) during heart development. Dev Dyn. 202:1995;115-125.
20. Liu L., Pasumarthi K.B., Padua R.R., et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am J Physiol. 268:1995;H1927-H1938.
21. Hughes S. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45:1997;1005-1019.
22. Mima T., Ueno H., Fischman D.A., Williams L.T., Mikawa T. Fibroblast growth factor receptor is required for in vivo cardiac myocyte proliferation at early embryonic stages of heart development. Proc Natl Acad Sci USA. 92:1995;467-471.
23. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr Rev. 18:1997;26-45.
24. Galzie Z., Kinsella A.R., Smith J.A. Fibroblast growth factors and their receptors. Biochem Cell Biol. 75:1997;669-685.
25. Kurobe M., Kato A., Takei Y., Hayashi K. Fluorometric enzyme immunoassay of basic fibroblast growth factor with monoclonal antibodies. Clin Chem. 38:1992;2121-2123.
26. Mignatti P., Morimoto T., Rifkin D.B. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol. 151:1992;81-93.
27. +-ATPase. J Biol Chem. 273:1998;544-551.
28. Oh J., Lee K. Possible implication for an indirect interaction between basic fibroblast growth factor and (Na,K)ATPase. Arch Pharm Res. 21:1998;707-711.
29. Gajdusek C.M., Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol. 139:1989;570-579.
30. Kaye D., Pimental D., Prasard S., et al. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest. 97:1996;281-291.
31. Floege J., Eng E., Lindner V., et al. Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest. 90:1992;2362-2369.
32. D'Amore P.A. Modes of FGF release in vivo and in vitro. Cancer Metastas Rev. 9:1990;227-238.
33. Thompson R.W., Whalen G.F., Saunders K.B., Hores T., D'Amore P.A. Heparin-mediated release of fibroblast growth factor-like activity into the circulation of rabbits. Growth Factors. 3:1990;221-229.
34. Saksela O., Rifkin D.B. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol. 110:1990;767-775.
35. Clarke M.S., Caldwell R.W., Chiao H., Miyake K., McNeil P.L. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res. 76:1995;927-934.
36. Cheng G.C., Briggs W.H., Gerson D.S., et al. Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res. 80:1997;28-36.
37. Ku P.T., D'Amore P.A. Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells. J Cell Biochem. 58:1995;328-343.
38. McNeil P.L., Muthukrishnan L., Warder E., D'Amore P.A. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol. 109:1989;811-822.
39. Piper H.M., Garcia-Dorado D. Prime causes of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg. 68:1999;1913-1919.
40. Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart. 83:2000;381-387.
41. Kardami E., Padua R., Pasumarthi K.B.S., et al. Basic fibroblast growth factor in cardiac myocytes: expression and effects. Cummins P. Growth factors and the cardiovascular system. 1993;55-75 Kluwer, Norwell, MA.
42. Padua R.R., Sethi R., Dhalla N.S., Kardami E. Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury. Mol Cell Biochem. 143:1995;129-135.
43. Cuevas P.F., Carceller F., Lozano R.M., et al. Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion. Growth Factors. 15:1997;29-40.
44. Padua R.R., Merle P.L., Doble B.W., et al. FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-dependent protein kinase C. J Mol Cell Cardiol. 30:1998;2659-2709.
45. Sheikh F., Sontag D.P., Fandrich R.R., Kardami E., Cattini P.A. Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol. 280:2001;H1039-H1050.
46. Jiang Z.S., Padua R.R., Ju H., et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol. 282:2002;H1071-H1080.
47. Harada K., Grossman W., Friedman M., et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest. 34:1994;623-630.
48. Horrigan M.C., Malycky J.L., Ellis S.G., Topol E.J., Nicolini F.A. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. Int J Cardiol. 68:1999;S85-S91.
49. Unger E.F., Banai S., Shou M., et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol Heart Circ Physiol. 266:1994;H1588-H1595.
50. Yanagisawa-Miwa A., Uchida Y., Nakamura F., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 257:1992;1401-1403.
51. Iwatate M., Miura T., Ikeda Y., et al. Effects of in vivo gene transfer of fibroblast growth factor-2 on cardiac function and collateral vessel formation in the microembolized rabbit heart. Jpn Circ J. 65:2001;226-231.
52. Hampton T.G., Amende I., Fong J., et al. Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. Am J Physiol Heart Circ Physiol. 279:2000;H260-H268.
53. Sheikh F. Regulation of the Fibroblast Growth Factor-2 Axis in Cardiac Cells: Effects on Cardioprotection and Cardiac Muscle Cell Growth. Thesis, University of Manitoba, Winnipeg, 2001.
54. Downey J.M., Cohen M.V. Signal transduction in ischemic preconditioning. Adv Exp Med Biol. 430:1997;39-55.
55. Cross H.R., Murphy E., Bolli R., Ping P., Steenbergen C. Expression of Activated PKC epsilon protects the ischemic heart, without attenuating ischemic H(+) production. J Mol Cell Cardiol. 34:2002;361-367.
56. Baines C.P., Zhang J., Wang G.W., et al. Mitochondrial PKC-epsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKC-epsilon-MAPK interactions and differential MAPK activation in PKC-epsilon-induced cardioprotection. Circ Res. 90:2002;390-397.
57. Ping P., Song C., Zhang J., et al. Formation of protein kinase C(epsilon)-Lck signaling modules confers cardioprotection. J Clin Invest. 109:2002;499-507.
58. ATP channels. J Cardiovasc Electrophysiol. 10:1999;741-754.
59. Tappia P.S., Padua R.R., Panagia V., Kardami E. Fibroblast growth factor-2 stimulates phospholipase Cbeta in adult cardiomyocytes. Biochem Cell Biol. 77:1999;569-575.
60. Fedorov Y.V., Jones N.C., Olwin B.B. Regulation of myogenesis by fibroblast growth factors requires beta-gamma subunits of pertussis toxin-sensitive G proteins. Mol Cell Biol. 18:1998;5780-5787.
61. Ping P., Zhang J., Qiu Y., et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 81:1997;404-414.
62. Liu H., Zhang H.Y., Zhu X., Shao Z., Yao Z. Preconditioning blocks cardiocyte apoptosis: role of K(ATP) channels and PKC-epsilon. Am J Physiol Heart Circ Physiol. 282:2002;H1380-H1386.
63. + ATP channels. Eur J Med Res. 5:2000;145-149.
64. Engelmann G.L., Dionne C.A., Jaye M.C. Acidic fibroblast growth factor and heart development. Role in myocyte proliferation and capillary angiogenesis. Circ Res. 72:1993;7-19.
65. Carden D.L., Granger D.N. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 190:2000;255-266.
66. Cuevas P., Carceller F., Ortega S., et al. Hypotensive activity of fibroblast growth factor. Science. 254:1991;1208-1210.
67. Doble B.W., Chen Y., Bosc D.G., Litchfield D.W., Kardami E. Fibroblast growth factor-2 decreases metabolic coupling and stimulates phosphorylation as well as masking of connexin43 epitopes in cardiac myocytes. Circ Res. 79:1996;647-658.
68. Doble B.W., Ping P., Kardami E. The epsilon subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. Circ Res. 86:2000;293-301.
69. Garcia-Dorado D., Inserte J., Ruiz-Meana M., et al. Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion. Circulation. 96:1997;3579-3586.
70. Ruiz-Meana M., Garcia-Dorado D., Hofstaetter B., Piper H.M., Soler-Soler J. Propagation of cardiomyocyte hypercontracture by passage of Na(+) through gap junctions. Circ Res. 85:1999;280-287.
71. Ishibashi Y., Urabe Y., Tsutsui H., et al. Negative inotropic effect of basic fibroblast growth factor on adult rat cardiac myocyte. Circulation. 96:1997;2501-2504.
72. Aiello E.A., Jabr R.I., Cole W.C. Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia. Role of oxygen radical-induced no-reflow phenomenon. Circ Res. 77:1995;153-162.
73. Sommerschild H.T., Kirkeboen K.A. Adenosine and cardioprotection during ischaemia and reperfusion - an overview. Acta Anaesthesiol Scand. 44:2000;1038-1055.
74. Albuquerque M.L., Akiyama S.K., Schnaper H.W. Basic fibroblast growth factor release by human coronary artery endothelial cells is enhanced by matrix proteins, 17beta-estradiol, and a PKC signaling pathway. Exp Cell Res. 245:1998;163-169.
75. Piotrowicz R.S., Martin J.L., Dillman W.H., Levin E.G. The 27-kDa heat shock protein facilitates basic fibroblast growth factor release from endothelial cells. J Biol Chem. 272:1997;7042-7047.
76. de Jager T., Pelzer T., Muller-Botz S., et al. Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. J Biol Chem. 276:2001;27873-27880.
77. Jin Y., Sheikh F., Detillieux K.A., Cattini P.A. Role for early growth response-1 protein in alpha(1)-adrenergic stimulation of fibroblast growth factor-2 promoter activity in cardiac myocytes. Mol Pharmacol. 57:2000;984-990.
78. Wang D., Mayo M.W., Baldwin A.S. Jr. Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. Oncogene. 14:1997;2291-2299.
79. Cuevas P., Carcellar F., Gimenez-Gallego G. Fibroblast growth factors in myocardial ischemia/reperfusion injury and ischemic preconditioning. J Cell Mol Med. 5:2001;132-142.
80. Buehler A., Martire A., Strohm C., et al. Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res. 55:2002;768-777.
81. Cuevas P., Carceller F., Martinez-Coso V., et al. Cardioprotection from ischemia by fibroblast growth factor: role of inducible nitric oxide synthase. Eur J Med Res. 4:1999;517-524.
82. Gumina R.J., Newman P.J., Kenny D., Warltier D.C., Gross G.J. The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury. Basic Res Cardiol. 92:1997;201-213.
83. Jordan J.E., Zhao Z.Q., Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 43:1999;860-878.
84. Entman M.L., Smith C.W. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res. 28:1994;1301-1311.
85. Woodley S.L., McMillan M., Shelby J., et al. Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation. 83:1991;1410-1418.
86. Meij J.T., Sheikh F., Jimenez S.K., et al. Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. Am J Physiol Heart Circ Physiol. 282:2002;H547-H555.
87. Weihrauch D., Tessmer J., Warltier D.C., Chilian W.M. Repetitive coronary artery occlusions induce release of growth factors into the myocardial interstitium. Am J Physiol. 275:1998;H969-H976.
88. Padua R.R., Kardami E. Increased basic fibroblast growth factor (bFGF) accumulation and distinct patterns of localization in isoproterenol-induced cardiomyocyte injury. Growth Factors. 8:1993;291-306.
89. Zhao X.M., Citrin B.S., Miller G.G., et al. Association of acidic fibroblast growth factor and untreated low grade rejection with cardiac allograft vasculopathy. Transplantation. 59:1995;1005-1010.
90. Poole T.J., Finkelstein E.B., Cox C.M. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn. 220:2001;1-17.
91. Leconte I., Fox J.C., Baldwin H.S., Buck C.A., Swain J.L. Adenoviral-mediated expression of antisense RNA to fibroblast growth factors disrupts murine vascular development. Dev Dyn. 213:1998;421-430.
92. Cox C.M., Poole T.J. Angioblast differentiation is influenced by the local environment: FGF-2 induces angioblasts and patterns vessel formation in the quail embryo. Dev Dyn. 218:2000;371-382.
93. Parsons-Wingerter P., Elliott K.E., Clark J.I., Farr A.G. Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. Arterioscler Thromb Vasc Biol. 20:2000;1250-1256.
94. Pohl T., Seiler C., Billinger M., et al. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol. 38:2001;1872-1878.
95. Epstein S.E., Fuchs S., Zhou Y.F., Baffour R., Kornowski R. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc Res. 49:2001;532-542.
96. Simons M., Laham R.J., Post M., Sellke F.W. Therapeutic angiogenesis: Potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease. BioDrugs. 14:2000;13-20.
97. Laham R.J., Post M., Sellke F.W., Simons M. Therapeutic angiogenesis using local perivascular and pericardial delivery. Curr Interv Cardiol Rep. 2:2000;213-217.
98. Tanaka K., Abe M., Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res. 90:1999;647-654.
99. Seghezzi G., Patel S., Ren C.J., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 141:1998;1659-1673.
100. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci. 110:1997;2293-2302.
101. Pepper M.S., Mandriota S.J., Jeltsch M., Kumar V., Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol. 177:1998;439-452.
102. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 189:1992;824-831.
103. Asahara T., Bauters C., Zheng L.P., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 92:1995;II365-II371.
104. Ueno H., Li J.J., Masuda S., et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 17:1997;2453-2460.
105. Ohara N., Koyama H., Miyata T., et al. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther. 8:2001;837-845.
106. Iwatate M., Miura T., Ikeda Y., et al. Effects of in vivo gene transfer of fibroblast growth factor-2 on cardiac function and collateral vessel formation in the microembolized rabbit heart. Jpn Circ J. 65:2001;226-231.
107. Isner J.M., Vale P.R., Symes J.F., Losordo D.W. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res. 89:2001;389-400.
108. Isner J.M. Myocardial gene therapy. Nature. 415:2002;234-239.
109. Sellke F.W., Laham R.J., Edelman E.R., Pearlman J.D., Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 65:1998;1540-1544.
110. Laham R.J., Sellke F.W., Edelman E.R., et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double blind, placebo-controlled trial. Circulation. 100:1999;1865-1871.
111. Laham R.J., Chronos N.A., Pike M., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol. 36:2000;2132-2139.
112. Udelson J.E., Dilsizian V., Laham R.J., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation. 102:2000;1605-1610.
113. Unger E.F., Goncalves L., Epstein S.E., et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol. 85:2000;1414-1419.
114. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 105:2002;788-793.
115. Pintucci G., Steinberg B.M., Seghezzi G., et al. Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases. Surgery. 126:1999;422-427.
116. Singh T.M., Abe K.Y., Sasaki T., et al. Basic fibroblast growth factor expression precedes flow-induced arterial enlargement. J Surg Res. 77:1998;165-173.
117. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. New Engl J Med. 316:1987;1371-1375.
118. Zarins C.K., Weisenberg E., Kolettis G., Stankunavicius R., Glagov S. Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. J Vasc Surg. 7:1988;386-394.
119. Bryant S.R., Bjercke R.J., Erichsen D.A., Rege A., Lindner V. Vascular remodeling in response to altered blood flow is mediated by fibroblast growth factor-2. Circ Res. 84:1999;323-328.
120. Yang H.T., Yan Z., Abraham J.A., Terjung R.L. VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol. 280:2001;H1097-H1104.
121. Fox J.C., Shanley J.R. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J Biol Chem. 271:1996;12578-12584.
122. Gospodarowicz D., Hirabayashi K., Giguere L., Tauber J.P. Factors controlling the proliferative rate, final cell density, and life span of bovine vascular smooth muscle cells in culture. J Cell Biol. 89:1981;568-578.
123. Karsan A., Yee E., Poirier G.G., et al. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol. 151:1997;1775-1784.
124. Ku P.T., D'Amore P.A. Regulation of basic fibroblast growth factor (bFGF) gene and protein expression following its release from sublethally injured endothelial cells. J Cell Biochem. 58:1995;328-343.
125. Schweigerer L., Malerstein B., Gospodarowicz D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun. 143:1987;997-1004.
126. Hanna A.K., Fox J.C., Neschis D.G., et al. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg. 25:1997;320-325.
127. Neschis D.G., Safford S.D., Hanna A.K., Fox J.C., Golden M.A. Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J Vasc Surg. 27:1998;126-134.
128. Hanna A.K., Duran W.N., Leconte I., et al. Adenoviral-mediated expression of antisense R. N.A. to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts. J Vasc Surg. 31:2000;770-780.
129. Pasumarthi K.B.S., Field L.J. Cardiomyocyte cell cycle regulation. Circ Res. 90:2002;1044-1054.
130. Anversa P., Nadal-Ginard B. Myocyte renewal and ventricular remodeling. Nature. 415:2002;240-243.
131. Greenberg B. Treatment of heart failure: state of the art and prospectives. J Cardiovasc Pharmacol. 38:(Suppl 2):2001;S59-S63.
132. Hoerstrup S.P., Zund G., Schnell A.M., et al. Optimized growth conditions for tissue engineering of human cardiovascular structures. Int J Artif Organs. 23:2000;817-823.
133. Pickering J.G., Ford C.M., Tang B., Chow L.H. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol. 17:1997;475-482.
134. Gutstein D.E., Morley G.E., Tamaddon H., et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 88:2001;333-339.
135. Parker T.G., Packer S.E., Schneider M.D. Peptide growth factors can provoke 'fetal' contractile protein gene expression in rat cardiac myocytes. J Clin Invest. 85:1990;507-514.
136. Corda S., Mebazaa A., Gandolfini M.P., et al. Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ Res. 81:1997;679-687.
137. Schultz J.E., Witt S.A., Nieman M.L., et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 104:1999;709-719.
138. Pellieux C., Foletti A., Peduto G., et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest. 108:2001;1843-1851.
139. Peifley K.A., Winkles J.A. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 242:1998;202-208.
140. Doble B.W., Kardami E. Basic fibroblast growth factor stimulates connexin-43 expression and intercellular communication of cardiac fibroblasts. Mol Cell Biochem. 143:1995;81-87.
141. Rook M.B., van Ginneken A.C., de Jonge B., et al. Differences in gap junction channels between cardiac myocytes, fibroblasts, and heterologous pairs. Am J Physiol. 263:1992;C959-C977.
142. Morrison R.S., Yamaguchi F., Saya H., et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol. 18:1994;207-216.
143. Reed M.J., Purohit A., Duncan L.J., et al. The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumors. J Steroid Biochem Mol Biol. 53:1995;413-420.
144. Halaban R. Growth factors and melanomas. Semin Oncol. 23:1996;673-681.
145. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 189:1999;72-78.
146. Dow J.K., deVere White R.W. Fibroblast growth factor-2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 55:2000;800-806.
147. Auguste P., Gursel D.B., Lemiere S., et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumour growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res. 61:2001;1717-1726.